#Bioretec #Finland #Tampere #stock options #Alan Donze

Bioretec Ltd Implements a New Stock Option Program for CEO Alan Donze

On March 21, 2025, Bioretec Ltd. announced the establishment of a new stock option program aimed at incentivizing and reinforcing the commitment of its Chief Executive Officer, Alan Donze. The decision, made by the company's Board of Directors during their meeting, aligns with the authorization granted at Bioretec's Annual General Meeting on the same day.

The rationale behind this initiative is substantial: the new stock options are intended to align the interests of the CEO with those of the company and its shareholders. By equipping Donze with these options, the Board hopes to further motivate his leadership and the long-term success of Bioretec.

Details of the Stock Option Program

The program will grant a total of 610,105 option rights to the CEO, each allowing for the acquisition of one share in the company. Importantly, these option rights will be issued at no cost to the CEO, which underscores Bioretec’s strategic investment in leadership. The timeline for exercising these rights is structured into distinct phases:

• - One-third of the options can be exercised starting from May 20, 2025.
• - The remaining two-thirds will be available in monthly installments of 1/24th, commencing June 20, 2025.

The final date to exercise these options will be December 31, 2030, providing a significant window for Donze to benefit from the program, given the right market conditions.

Pricing and Valuation of Shares

The price for shares acquired through the option rights is set at EUR 2.79, which reflects a 10% increase from the trade volume-weighted average price of Bioretec shares on Nasdaq Helsinki during the period from December 20, 2024, to March 20, 2025. This pricing structure is designed to account for market conditions and ensures that leadership rewards are fair and competitive.

As a result of this option program, Bioretec's total share count could potentially increase by up to 610,105 shares, roughly equating to about 2.48% of the company’s total shares and voting rights post-exercise.

Implications for Bioretec and Its Future

The introduction of this stock option program is a pivotal move for Bioretec, a company recognized for its innovative work in biodegradable orthopedic implants. These implants enhance bone growth and expedite healing processes, aiming to redefine standards in the medical device industry. With such strategic initiatives, Bioretec is positioning itself to make significant advancements within the global orthopedic trauma and spine market, which is valued at over USD 9 billion.

Bioretec's current product line includes the RemeOs™ implant series, praised for their ability to be absorbed by bone, eliminating the need for removal surgery, and achieving better healthcare efficiency while focusing on patient value. The market authorization for RemeOs™ in the U.S. was granted in March 2023, with European approval following in January 2025.

This new program serves as both an incentive for Bioretec's leadership and a commitment to its growth trajectory in a highly competitive industry sector. As the company continues to innovate and expand, the partnership between the Board, CEO Alan Donze, and stakeholders will be essential in driving Bioretec towards its ambitious goals.

For inquiries related to this stock option program, contact Kustaa Poutiainen, Chairperson of the Board, via +358 40 042 4506.